Your browser doesn't support javascript.
loading
Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
Sho Miyamoto; Takeshi Arashiro; Akira Ueno; Takayuki Kanno; Shinji Saito; Harutaka Katano; Shun Iida; Akira Ainai; Seiya Ozono; Takuya Hemmi; Yuichiro Hirata; Saya Moriyama; Ryutaro Kotaki; Hitomi Kinoshita; Souichi Yamada; Masaharu Shinkai; Shuetsu Fukushi; Yoshimasa Takahashi; Tadaki Suzuki.
Afiliação
  • Sho Miyamoto; National Institute of Infectious Diseases
  • Takeshi Arashiro; National Institute of Infectious Diseases
  • Akira Ueno; National Institute of Infectious Diseases
  • Takayuki Kanno; National Institute of Infectious Diseases
  • Shinji Saito; National Institute of Infectious Diseases
  • Harutaka Katano; National Institute of Infectious Diseases
  • Shun Iida; National Institute of Infectious Diseases
  • Akira Ainai; National Institute of Infectious Diseases
  • Seiya Ozono; National Institute of Infectious Diseases
  • Takuya Hemmi; National Institute of Infectious Diseases
  • Yuichiro Hirata; National Institute of Infectious Diseases
  • Saya Moriyama; National Institute of Infectious Diseases
  • Ryutaro Kotaki; National Institute of Infectious Diseases
  • Hitomi Kinoshita; National Institute of Infectious Diseases
  • Souichi Yamada; National Institute of Infectious Diseases
  • Masaharu Shinkai; Tokyo Shinagawa Hospital
  • Shuetsu Fukushi; National Institute of Infectious Diseases
  • Yoshimasa Takahashi; National Institute of Infectious Diseases
  • Tadaki Suzuki; National Institute of Infectious Diseases
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22276432
ABSTRACT
AbstractImmunity to SARS-CoV-2 in COVID-19 cases has diversified due to complex combinations of exposure to vaccination and infection. Elucidating the drivers for upgrading neutralizing activity to SARS-CoV-2 in COVID-19 cases with pre-existing immunity will aid in understanding immunity to SARS-CoV-2 and improving COVID-19 booster vaccines with enhanced cross-protection against antigenically distinct variants. This study revealed that the magnitude and breadth of neutralization responses to SARS-CoV-2 infection in breakthrough infections are determined by upper respiratory viral load and vaccination-infection time interval, but not by the lineage of infecting viruses. Notably, the time interval, but not the viral load, may play a critical role in expanding the breadth of neutralization to SARS-CoV-2. This illustrates the importance of dosing interval optimization in addition to antigen design in the development of variant-proof booster vaccines. One-Sentence SummaryViral load and infection timing define the magnitude and breadth of SARS-CoV-2 neutralization after breakthrough infection.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
...